Prostate cancer is the most common cancer affecting the male population in the United States. The incidence is 70% higher in black men as compared to whites. The incidence of metastatic castration-resistant prostate cancer (an advanced state of this cancer) is increasing at an alarming rate of 5% every year. Therefore, there is an emphasis on developing high-quality and potent drugs for the disease.
The Metastatic Castration-Resistant Prostate Cancer Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into metastatic castration-resistant prostate cancer drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Metastatic castration-resistant prostate cancer. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The metastatic castration-resistant prostate cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from metastatic castration-resistant prostate cancer.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to metastatic castration-resistant prostate cancer.
Metastatic castration-resistant prostate cancer is an advanced state of prostate cancer that has spread to other parts of the body such as lymph nodes, rectum, liver, lungs or bones. In this state of cancer, the body stops responding to hormone treatment that is responsible for lowering testosterone levels and slowing down disease progression in patients. Signs and symptoms may depend on tumor size and areas where it has spread. Pain or blood while urinating, shortness of breath, fatigue and weight loss are common symptoms. Although androgen deprivation therapy (ADT) or hormone therapy may not work, patients are still kept on these therapies as there is a chance that some cancerous cells may respond to them. Other treatment alternatives involve chemotherapy, immunotherapy, radioactive materials, and others.
To combat the rising mortality and comorbidity rate associated with the disease, several drugs have been approved by the FDA in 2023. For instance, in August 2023, a combination of niraparib and abiraterone acetate tablets (Akeega) with prednisone received the FDA’s green signal. In addition, the combination Talazoparib (a PARP inhibitor) and enzalutamide received FDA approval and a marketing authorisation by the EMA in June 2023.
This section of the report covers the analysis of metastatic castration-resistant prostate cancer drugs based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for metastatic castration-resistant prostate cancer. There are around 509 drugs in phase II of metastatic castration-resistant prostate cancer drugs.
The drug molecules categories covered under metastatic castration-resistant prostate cancerpipeline analysis include androgen receptor signal inhibitors, CYP17 inhibitors, chemotherapy, immunotherapy, bone-targeted therapy and radiopharmaceuticals. Treatment strategies are decided on the basis of multiple factors such as side effects and the overall health of the patients.
The EMR report for the metastatic castration-resistant prostate cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in metastatic castration-resistant prostate cancer clinical trials:
Sponsored by Janssen Research & Development, LLC, JNJ-78278343 is being investigated to treat metastatic castration-resistant prostate cancer (mCRPC) with confirmed adenocarcinoma of the prostate. The drug is in Phase 1 study and will be administered in combination with either Taxane chemotherapy, Cetrelimab (JNJ-63723283) or androgen receptor pathway inhibitors.
Amgen's AMG 340 is being evaluated to treat metastatic castration resistant prostate cancer. This PSMAxCD3 T-cell engaging bispecific antibody is in Phase 1 of an open-label study with 2 arms, namely, a monotherapy dose escalation (Arm A) and a monotherapy dose expansion (Arm B).
This drug is under investigation to treat metastatic castration resistant prostate in adults. Sponsored by Bristol-Myers Squibb, the drug is in Phase 1 of an open-label study with 90 enrolled participants.
Researchers at the University of Alabama at Birmingham are evaluating Carfilzomib for its efficacy against metastatic castration-resistant prostate cancer (CRPC). Previously approved for multiple myeloma treatment, the drug is being assessed to reduce prostate cancer progression in patients who have received chemotherapy and androgen inhibitors in the past. It is currently in Phase 2 of the trial.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Metastatic Castration-Resistant Prostate Cancer Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for metastatic castration-resistant prostate cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within metastatic castration-resistant prostate cancer pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Androgen Receptor Signal Inhibitors |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share